Steven Narod, M.D., Ph.D.
Professor
Departments of Public Health Sciences and Nutritional Sciences, Canada Research Chair in Breast Cancer

Ph: 416.351.3765
Fax: 416.351.3767
steven.narod@wchospital.ca


Primary Affiliations:

• Director, Familial Breast Cancer Research Unit, Women’s College Research Institute
  

Other Affilliations:

• Professor, Dalla Lana School of Public Health, University of Toronto

Education/Degrees:

• MD, FRCPC

Awards/Recognition:

• Tier 1 Canada Research Chair in Breast Cancer
• Honorary PhD, Pomeranian Medical University

Current Students:

• Adriana Valentini (Master’s degree candidate)

Research:

• Dr. Narod conducts longitudinal studies of women from families with and without genetic mutations related to breast cancer. He is currently focused on translating our emerging knowledge about hereditary cancer into more effective strategies for the prevention and management of breast and ovarian cancer. He is also interested in delineating the gene/environment interactions that underlie hereditary breast cancer. This work may eventually be used to identify potential modifiers of cancer risk in high-risk groups. He is currently principal investigator on a number of studies looking at risk factors associated with hereditary breast and ovarian cancer, investigating the role of BRCA2 mutations in ovarian cancer, and investigating the contributions of CHK2 gene mutations to breast cancer risk. He also participates as a co-investigator on a wide-range of hereditary cancer studies conducted by his students and international colleagues.

Recent Publications:                                                   

 

1. Narod SA, Iqbal J. Tamoxifen chemoprevention and cardiac disease. J Clin Oncol, 29: 3106-7, 2011.
2. Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JK, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers. Cancer Epidemiol Biomarkers Prev, 20: 1690-702, 2011.
3. Nam RK, Kattan MW, Chil JL, Trachtenberg J, Singal R, Rendon R, Klotz LH, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, Diamandis EP, Yu C, Loblaw DA, Narod SA. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol, 29: 2959-64, 2011.
4. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer, 117: 1812-8, 2011.
5. Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J, 5: E31-5, 2011.
6. Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, Narod SA, Warner E. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast, 20: 254-8, 2011.
7. Raskin L, Schwenter F, Freytsis M, Tischkowitz M, Wong N, Chong G, Narod SA, Levine DA, Bogomolniy D, Aronson M, Thibodeau SN, Hunt KS, Rennert G, Gallinger S, Gruber SB, Doulkes WD. Characterization of two Ashkenazi Jewish founder mutations in MCH6 gene causing Lynch syndrome. Clin Genet, 79: 512-22, 2011.
8. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Lynch HT, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Armel S, Huzarski T, Ainsworth P, Pollak M, Sun P, Narod SA, Hereditary Breast Cancer Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer, 117: 1812-8, 2011.
9. Narod SA. Screening of women at high risk of breast cancer. Prev Med. 1:127-30, 2011.
10. Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojc B, Debniak T, Gorski B, Blencharz P, Narod SA, Lubinski J. Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. J Clin Oncol. 29: 3747-52, 2011.
11. Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. Maturitas. 70: 261-5, 2011.
12. Akbari MR, Zhang S, Fan I, Royer R, Li S, Risch H, McLaughlin J, Rosen B, Sun P, Narod SA. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. J Med Gen, 48: 783-6, 2011.
13. Narod SA. Early-onset breast cancer: what do we know about the risk factors? : A Countercurrents Series. Curr Oncol. 18: 204-5, 2011.
14. Narod SA. Alcohol and risk of breast cancer. JAMA, 306: 1920-1, 2011.
15. Narod SA., Salmena L. BRCA1 and BRCA2 mutations and breast cancer. Discov Med, 12: 445-53, 2011.
16. Koupis C, Dimitrakakis C, Antsaklis A, Royer R, Zhang S, Narod SA., Kotsopoulos J. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. Hered Cancer Clin Pract, 9:10, 2011.
17. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol, 8: 669-76, 2011.
18. Narod SA. Earlier age of onset in BRCA carriers-anticipation or cohort effect? : A Countercurrents Series. Curr Oncol, 18: 257-8, 2011.
19. Narod SA., Rodriquez AA. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes]. Salud Publica Mex. 53: 420-9, 2011.
20. Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, Tonin PN. The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat. 131: 333-40, 2012.
21. Kotsopoulos J, Narod SA. Androgens and breast cancer. Steroids, 77:1-9, 2012.
22. Narod SA. Should all Women with Breast Cancer be Tested for BRCA mutations at the Time of Diagnosis? J of Clin Oncol, 30: 2-3, 2012.
23. Rodriquez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, Narod SA. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol, 124: 236-43, 2012.
24. Iqbal J, Ginsburg OM, Thiwanka W, Narod SA. Endometrial cancer and venous thromoembolic events in women under age 50 years who take tamoxifen for breast cancer prevention: a systematic review. Cancer Treat Rev. 2011 Jul 18 (Epub ahead of Print)
25. Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, Foulkes WD, Kilar E, Kim-Sing C, Neuhausen SL, Tung N, Armel S, Gilchrist D, Ainsworth P, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA. The Risk of Breast Cancer in Women with a BRCA1 Mutation from North America and Poland. International Journal of Cancer. 2011 Aug 29 (Epub ahead of Print)
26. Gutierrez Espeleta GA, Llacuachaqui M, Garcia-Jimenez L, Herrera MA, Vega KL, Ortiz A, Royer R, Li S, Narod SA. BRCA1 and BRCA2 Mutations among Familial Breast Cancer Patients from Costa Rica. Clin Genet. 2011 Sep 5 (Epub ahead of Print)
27. Han K, Nofech-Mozes S, Narod SA, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E. Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence. Clin Oncol (R Coll Radiol), 2011 Sep 27 (Epub ahead of Print)
28. Al-Sukhni W, Bordiga A, Rothenmund H, Holdter S, Semotiuk K, Grant R, Wilson S, Moore M, Narod SA, Jhaveri K, Haider MA, Gallinger S. Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience. J Gastrointest Surg, 2011 Nov 30. (Epub ahead of print).
29. Metcalfe KA, Mian N, Enmore E, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat, 2012 Jan 13. (Epub ahead of print).
30. Stevens KN, Kelemen LE, Wang C, Fridley BL, Vierkant RA, Fredericksen Z, Armasu SM, Tsai YY, Berchuck A, Association Consortium OC, Narod SA, Phelan CM, Sutphen R, Birrer MJ, Schildkraut JM, Sellers TA, Goode EL, Couch FJ. Common variation in Nemo-like kinase (NLK) is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2012 Jan 17. (Epub ahead of print).
31. Mcgee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim=Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA. Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. Obesity (Silver Spring), 2012 Jan 19. (Epub ahead of print).
32. Narod SA. A model for breast cancer risk based on stem cell theory. Current Oncology. (In press).
    
    PubMed